期刊文献+

来氟米特治疗激素无效的HSPN临床观察 被引量:2

Clinical observation on effect of LEF in treating HSPN
下载PDF
导出
摘要 目的探讨来氟米特(LEF)治疗HSPN疗效。方法将26例激素无效HSPN随机分为试验组13例,对照组13例。试验组用强的松加LEF,对照组用强的松加环磷酰胺(CTX)。试验组LEF负荷剂量50mg/d,晨起顿服,共3天;而后改为20mg/d,维持至6个月。对照组CTX每月连续应用2天,每月用量为1g,总疗程6个月。观察治疗前后24小时尿蛋白定量(24hU-PRO)、血浆白蛋白、血清肌酐、内生肌酐清除率(Ccr)及患者的不良反应。结果试验组的完全缓解率为53.8%,总有效率为84.6%。对照组的完全缓解率为46.2%,总有效率为76.9%。试验组与对照组之间比较无统计学意义(P>0.05)。在治疗过程中及治疗结束后两组患者的肾功能较治疗前均无明显变化(P>0.05)。结论 LEF联合强的松治疗激素无效的HSPN是安全和有效的。 Objective To explore the efficacy of leflunomide (LEF) treatment of HSPN. Methods Selected 26 cases of hormone invalid HSPN, 13 cases divided into test group, control group 13 cases. Test group with glucocorticoid and LEF, the control group with glueocorticoid eyclophosphamide (CTX). Test group LEF loading dose of 50 mg / d , early morning serving Dayton, a total of three days; Then changed to 20rag / d, maintained up to 6 months. Control group , CTX monthly application of two days, monthly dosage of lg, total treatment duration was 6 months. Observed before and after treatment 24 hour urinary protein excretion (24h U --PRO ) , Serum albumin, serum creatinine, endog- enous creatinine clearance rate (Cer) in patients with adverse reactions. Conclusions LEF combined with prednisone in the treatment of hormone invalid the HSPN is safe and effective.
作者 刘会萍
出处 《齐齐哈尔医学院学报》 2012年第11期1431-1432,共2页 Journal of Qiqihar Medical University
  • 相关文献

参考文献7

  • 1Bergstein J, Leiser J, Anderoli SP. Response of crescentic Hench --Schonlein purpura nephritis to corticosteroid and azathioprine therapy[J]. Cin Nephrol, 1998,49 : 9.
  • 2Kunis CL, Kiss B, Williams G, et al. Treatment of rapidly pro- gressive glomerulonephritis to corticosteroid and azathioprine theraphy[J]. CinNephrol, 1998,12 : 238.
  • 3Iijima K,Ito Kariya S,Nakamura H,et. Multiple combined ther- apy for severe Hench--Schonlein nephritis in children[J]. Pedi- atr Nephrol, 1998,12 : 244.
  • 4Miceli Richard C,Dougados M. Leflunomide for the treatment of rheumatoid arthritis[J]. Expert Opin Phamacother, 2003,4 (6) : 987-997.
  • 5Urushibarn M, Takayarnagi H, Koga T, et al. The antirheumatic drug leflunmide inhibits osteoclastogenesis by interfering with receptor activator of NF--kappa B ligand--stimulated induction of nuclear factor of activated T cells[J]. Arthritis Rheum, 2004, 50(3) :794-804.
  • 6赵珉,张伯科,王坤,钱浩,戴宏,梁维龙,阚春明.来氟米特对大鼠肾毒血清性肾炎早期肾损害的保护作用[J].安徽医科大学学报,2006,41(3):290-293. 被引量:6
  • 7Petya Dimitrova, Alia Skapenko, Matthias L, et al. Restriction of denovo pyrimidine biosynthesis inhibits Thl cell activation and promotes The Cell differentiation[J]. Immu, 2002,169 (6) : 3 -392.

二级参考文献11

  • 1Schreiner G F.Cotron R S.Pardo V,et al.A monocyte cell component in experiment immunological glomernlonephritis[J].J Exp Med,1978,147(2):369-84
  • 2Mizuki S, Yumiko N, Kazuhiro I, et al. Expression monocyte chemoattractant protein-1 in experimental crescentic glomerulonephritis in rats[J]. J Lab Clin Med,1997,129(2) : 239 -44.
  • 3Masato I, Hidehiko F, Laxman P, et al. Important role of macrophages in induction of crescentic anti - GBM glomerulonephritis in WKY rats[ J ]. Nephrol Dial Transplant, 2004,19 ( 12 ) : 2997 -3004.
  • 4Ikezumi Y, Hurst L A, Masaki T, et al. Adoptive transfer studies demonstrate that macrophage can induce proteinuria and mesangial cell proliferation [J]. Kidney Int,2003,63( 1 ) : 83 -95.
  • 5Segerer S, Nelson P J, Schlφndorff D. Chemokines, chemokine receptors, and renal disease: From basic science to pathophysiologic and therapeutic study [ J ]. J Am Soc Nephrol, 2000, 11 :152 -76.
  • 6Fujinaka H, Yamamoto T, Takeya M, et al. Suppression of antiglomemlar basement membrane nephritis by antibody in WKY rats[J]. J Am Soc Nephrol, 1997, 8:1174 -8.
  • 7Jaimes H J, Robles-San, Roman M, et al. Rheumatoid arthritis treatment with weekly leflunomide: an open-label study [ J ]. J Rheumatol, 2004, 31(2): 235 -7.
  • 8Williams J W, Mital D, Chong A, et al. Experiences with leflunomide in solid organ transplantation [ J ]. Transplantation, 2002,73(3) : 358 -66.
  • 9Remer C F, Weisman M H, Wallace D J. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study [ J]. Lupus, 2001, 10(7): 480-3.
  • 10Ogawa T, Inazu M, Gotoh K, et al. Effects of leflunomide on glomemlonephritis induced by antibasement membrane antibody in rat[J]. Agents Actions, 1990, 31(3 -4) : 321 -8.

共引文献5

同被引文献25

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部